Trexquant Investment LP Acquires 486,827 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Trexquant Investment LP lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 101.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 966,049 shares of the biopharmaceutical company's stock after acquiring an additional 486,827 shares during the quarter. Trexquant Investment LP owned approximately 0.32% of Amicus Therapeutics worth $9,100,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Amicus Therapeutics during the third quarter valued at about $55,000. R Squared Ltd purchased a new stake in shares of Amicus Therapeutics during the 4th quarter valued at approximately $79,000. KBC Group NV boosted its holdings in Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 3,120 shares during the period. Sciencast Management LP bought a new position in shares of Amicus Therapeutics in the fourth quarter worth $100,000. Finally, Stephens Inc. AR purchased a new position in shares of Amicus Therapeutics in the fourth quarter valued at $101,000.

Amicus Therapeutics Trading Down 4.9 %

Shares of NASDAQ:FOLD traded down $0.37 on Monday, reaching $7.13. 1,356,214 shares of the company traded hands, compared to its average volume of 2,530,816. The stock has a market capitalization of $2.19 billion, a P/E ratio of -39.25, a price-to-earnings-growth ratio of 1.51 and a beta of 0.79. The business's 50-day simple moving average is $9.12 and its 200 day simple moving average is $9.84. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 52 week low of $6.99 and a 52 week high of $12.65.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on FOLD shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, February 20th. Wells Fargo & Company decreased their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.